Sex steroid actions in male bone

Endocrine Reviews

Volumn 35, Issue 6, 2014, Pages 906-960

  Vanderschueren, Dirk ^a   Laurent, Michaël R ^a,b,c   Claessens, Frank ^c   Gielen, Evelien ^a,b   Lagerquist, Marie K ^d   Vandenput, Liesbeth ^d   Börjesson, Anna E ^d   Ohlsson, Claes ^d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Gerontology and Geriatrics   (Belgium)

^c Department of Clinical and Experimental Medicine   (Belgium)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GONADOTROPIN; SEX HORMONE; ANDROGEN; ESTROGEN;

BODY COMPOSITION; BONE DEVELOPMENT; BONE GROWTH; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE STRENGTH; BONE TISSUE; CARTILAGE CELL; CELL LINEAGE; CORTICAL BONE; DNA BINDING; ESTRADIOL BLOOD LEVEL; HUMAN; MALE; MUSCLE MASS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOPOROSIS; POROSITY; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STEROID METABOLISM; TARGET CELL; TRABECULAR BONE; AGING; ANIMAL; BONE; CYTOLOGY; FEMALE; METABOLISM; MOUSE; PHYSIOLOGY;

AGING; ANDROGENS; ANIMALS; BONE AND BONES; ESTROGENS; FEMALE; HUMANS; MALE; MICE; OSTEOGENESIS; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

EID: 84920100149     PISSN: None     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2014-1024     Document Type: Review

References (458)

1. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29:441-464.
2. Orwoll ES, Bilezikian JP, Vanderschueren D. Osteoporosis in Men: The Effects of Gender on Skeletal Health. 2nd ed. London, UK: Elsevier Science; 2010.
3. Nguyen ND, Ahlborg HG, Center JR, Eisman JA, Nguyen TV. Residual lifetime risk of fractures in women and men. J Bone Miner Res. 2007;22:781-788.
4. Lippuner K, Johansson H, Kanis JA, Rizzoli R. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int. 2009;20:1131-1140.
5. Ahmed LA, Schirmer H, Bjørnerem A, et al. The genderand age-specific 10-year and lifetime absolute fracture risk in Tromsø, Norway. Eur J Epidemiol. 2009;24:441-448.
6. Kanis JA, Odén A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23:2239-2256.
7. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733.
8. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475.
9. Donaldson LJ, Reckless IP, Scholes S, Mindell JS, Shelton NJ. The epidemiology of fractures in England. J Epidemiol Community Health. 2008;62:174-180.
10. Bergström U, Björnstig U, Stenlund H, Jonsson H, Svensson O. Fracture mechanisms and fracture pattern in men and women aged 50 years and older: a study of a 12-year population-based injury register, Umeå, Sweden. Osteoporos Int. 2008;19:1267-1273.
11. Haentjens P, Magaziner J, Colón-Emeric CS, et al. Metaanalysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152:380-390.
12. Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing. 2010;39:203-209.
13. Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297:387-394.
14. Tarride JE, Guo N, Hopkins R, et al. The burden of illness of osteoporosis in Canadian men. J Bone Miner Res. 2012;27:1830-1838.
15. Curtis JR, McClure LA, Delzell E, et al. Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med. 2009;24:956-962.
16. Nurmi-Lüthje I, Sund R, Juntunen M, Lüthje P. Post-hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: a nationwide study in Finland. J Bone Miner Res. 2011;26:1845-1853.
17. Leslie WD, LaBine L, Klassen P, Dreilich D, Caetano PA. Closing the gap in postfracture care at the population level: a randomized controlled trial. CMAJ. 2012;184:290-296.
18. Wastesson JW, Ringbäck Weitoft G, Parker MG, Johnell K. Educational level and use of osteoporosis drugs in elderly men and women: a Swedish nationwide registerbased study. Osteoporos Int. 2013;24:433-442.
19. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367:1714-1723.
20. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13:763-773.
21. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279-302.
22. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010;31:266-300.
23. Khosla S, Melton LJ 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26:441-451.
24. Khosla S, Bellido TM, Drezner MK, et al. Forum on aging and skeletal health: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2011;26:2565-2578.
25. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genomewide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44:491-501.
26. Liu CT, Estrada K, Yerges-Armstrong LM, et al. Assessment of gene-by-sex interaction effect on bone mineral density. J Bone Miner Res. 2012;27:2051-2064.
27. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev. 2004;25:389-425.
28. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-1822.
29. Laurent M, Gielen E, Claessens F, Boonen S, Vanderschueren D. Osteoporosis in older men: recent advances in pathophysiology and treatment. Best Pract Res Clin Endocrinol Metab. 2013;27:527-539.
30. Lindle RS, Metter EJ, Lynch NA, et al. Age and gender comparisons of muscle strength in 654 women and men aged 20-93 yr. J Appl Physiol (1985). 1997;83:1581-1587.
31. Visser M, Fuerst T, Lang T, Salamone L, Harris TB. Validity of fan-beam dual-energy x-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition Study-Dual-Energy X-ray Absorptiometry and Body Composition Working Group. J Appl Physiol (1985). 1999;87:1513-1520.
32. Gielen E, Verschueren S, O'Neill TW, et al. Musculoskeletal frailty: a geriatric syndrome at the core of fracture occurrence in older age. Calcif Tissue Int. 2012;91:161-177.
33. Giannoulis MG, Martin FC, Nair KS, Umpleby AM, Sonksen P. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev. 2012;33:314-377.
34. Renoud A, Ecochard R, Marchand F, Chapurlat R, Szulc P. Predictive parameters of accelerated muscle loss in men-MINOS study. Am J Med. 2014;127:554-561.
35. Fazeli PK, Horowitz MC, MacDougald OA, et al. Marrow fat and bone-new perspectives. J Clin Endocrinol Metab. 2013;98:935-945.
36. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833-876.
37. Labrie F, Cusan L, Gomez JL, et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol. 2009;113:52-56.
38. de Ronde W, van der Schouw YT, Pols HA, et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin Chem. 2006;52:1777-1784.
39. Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf). 2010;73:382-388.
40. Ohlsson C, Wallaschofski H, Lunetta KL, et al. Genetic determinants of serum testosterone concentrations in men. PLoS Genet. 2011;7:e1002313.
41. Laurent MR, Vanderschueren D. Reproductive endocrinology: functional effects of sex hormone-binding globulin variants. Nat Rev Endocrinol. 2014;10:516-517.
42. Rosner W, Auchus RJ, Azziz R, Sluss PM, RaffH. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405-413.
43. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab. 2006;91:1336-1344.
44. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96:2430-2439.
45. Naessen T, Sjogren U, Bergquist J, Larsson M, Lind L, Kushnir MM. Endogenous steroids measured by highspecificity liquid chromatography-tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old men and women. J Clin Endocrinol Metab. 2010;95:1889-1897.
46. Huhtaniemi IT, Tajar A, Lee DM, et al. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol. 2012;166:983-991.
47. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab. 2013;98:3971-3973.
48. Ohlsson C, Nilsson ME, Tivesten A, et al. Comparisons of immunoassay and mass spectrometry measurements of serum estradiol levels and their influence on clinical association studies in men. J Clin Endocrinol Metab. 2013;98: E1097-E1102.
49. Khosla S, Amin S, Singh RJ, Atkinson EJ, Melton LJ 3rd, Riggs BL. Comparison of sex steroid measurements in men by immunoassay versus mass spectroscopy and relationships with cortical and trabecular volumetric bone mineral density. Osteoporos Int. 2008;19:1465-1471.
50. Peng Z, Li X, Mäkelä S, Väänänen HK, Poutanen M. Skeletal changes in transgenic male mice expressing human cytochrome P450 aromatase. J Bone Miner Res. 2004;19:1320-1328.
51. Sjögren K, Lagerquist M, Moverare-Skrtic S, et al. Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects. J Bone Miner Res. 2009;24:1263-1270.
52. Windahl SH, Andersson N, Börjesson AE, et al. Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice. PLoS One. 2011;6:e21402.
53. Vandenput L, Labrie F, Mellström D, et al. Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Miner Res. 2007;22:220-227.
54. Lorentzon M, Eriksson AL, Mellström D, Ohlsson C. The COMT val158met polymorphism is associated with peak BMD in men. J Bone Miner Res. 2004;19:2005-2011.
55. Lorentzon M, Eriksson AL, Nilsson S, Mellström D, Ohlsson C. Association between physical activity and BMD in young men is modulated by catechol-O-methyltransferase (COMT) genotype: the GOOD study. J Bone Miner Res. 2007;22:1165-1172.
56. Stolk L, van Meurs JB, Jhamai M, et al. The catechol-O-methyltransferase Met158 low-activity allele and association with nonvertebral fracture risk in elderly men. J Clin Endocrinol Metab. 2007;92:3206-3212.
57. Eriksson AL, Mellström D, Lorentzon M, et al. The COMT val158met polymorphism is associated with prevalent fractures in Swedish men. Bone. 2008;42:107-112.
58. Yarrow JF, Conover CF, Lipinska JA, Santillana CA, Wronski TJ, Borst SE. Methods to quantify sex steroid hormones in bone: applications to the study of androgen ablation and administration. Am J Physiol Endocrinol Metab. 2010;299:E841-E847.
59. Helsen C, Kerkhofs S, Clinckemalie L, et al. Structural basis for nuclear hormone receptor DNA binding. Mol Cell Endocrinol. 2012;348:411-417.
60. Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, Haelens A. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal. 2008;6:e008.
61. Sahu B, Pihlajamaa P, Dubois V, Kerkhofs S, Claessens F, Jänne OA. Androgen receptor uses relaxed response element stringency for selective chromatin binding and transcriptional regulation in vivo. Nucleic Acids Res. 2014;42:4230-4240.
62. Schauwaers K, De Gendt K, Saunders PT, et al. Loss of androgen receptor binding to selective androgen response elements causes a reproductive phenotype in a knockin mouse model. Proc Natl Acad Sci USA. 2007;104:4961-4966.
63. Mödder UI, Sanyal A, Kearns AE, et al. Effects of loss of steroid receptor coactivator-1 on the skeletal response to estrogen in mice. Endocrinology. 2004;145:913-921.
64. Langer G, Bader B, Meoli L, et al. A critical review of fundamental controversies in the field of GPR30 research. Steroids. 2010;75:603-610.
65. Kim KH, Toomre D, Bender JR. Splice isoform estrogen receptors as integral transmembrane proteins. Mol Biol Cell. 2011;22:4415-4423.
66. Rudnik V, Sanyal A, Syed FA, et al. Loss of ERE binding activity by estrogen receptor-α alters basal and estrogenstimulated bone-related gene expression by osteoblastic cells. J Cell Biochem. 2008;103:896-907.
67. Ciana P, Raviscioni M, Mussi P, et al. In vivo imaging of transcriptionally active estrogen receptors. Nat Med. 2003;9:82-86.
68. Jänne M, Deol HK, Power SG, Yee SP, Hammond GL. Human sex hormone-binding globulin gene expression in transgenic mice. Mol Endocrinol. 1998;12:123-136.
69. Toran-Allerand CD, Tinnikov AA, Singh RJ, Nethrapalli IS. 17α-estradiol: a brain-active estrogen? Endocrinology. 2005;146:3843-3850.
70. McNamara KM, Harwood DT, Simanainen U, Walters KA, Jimenez M, Handelsman DJ. Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol. 2010;121:611-618.
71. Vandenput L, Swinnen JV, Boonen S, et al. Role of the androgen receptor in skeletal homeostasis: the androgenresistant testicular feminized male mouse model. J Bone Miner Res. 2004;19:1462-1470.
72. Haisenleder DJ, Schoenfelder AH, Marcinko ES, Geddis LM, Marshall JC. Estimation of estradiol in mouse serum samples: evaluation of commercial estradiol immunoassays. Endocrinology. 2011;152:4443-4447.
73. Vandenput L, Ederveen AG, Erben RG, et al. Testosterone prevents orchidectomy-induced bone loss in estrogen receptor-α knockout mice. Biochem Biophys Res Commun. 2001;285:70-76.
74. McDougall KE, Perry MJ, Gibson RL, Colley SM, Korach KS, Tobias JH. Estrogen receptor-α dependency of estrogen's stimulatory action on cancellous bone formation in male mice. Endocrinology. 2003;144:1994-1999.
75. Lapauw B, Taes Y, Simoens S, et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone. 2008;43:1016-1021.
76. Perrien DS, Akel NS, Edwards PK, et al. Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology. 2007;148:1654-1665.
77. Matsumoto C, Inada M, Toda K, Miyaura C. Estrogen and androgen play distinct roles in bone turnover in male mice before and after reaching sexual maturity. Bone. 2006;38:220-226.
78. Callewaert F, Venken K, Kopchick JJ, et al. Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: evidence from pubertal mouse models. J Bone Miner Res. 2010;25:617-626.
79. Yu S, Zhang C, Lin CC, et al. Altered prostate epithelial development and IGF-1 signal in mice lacking the androgen receptor in stromal smooth muscle cells. Prostate. 2011;71:517-524.
80. Yeh S, Tsai MY, Xu Q, et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA. 2002;99:13498-13503.
81. Kawano H, Sato T, Yamada T, et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA. 2003;100:9416-9421.
82. Venken K, De Gendt K, Boonen S, et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res. 2006;21:576-585.
83. MacLean HE, Chiu WS, Notini AJ, et al. Impaired skeletal muscle development and function in male, but not female, genomic androgen receptor knockout mice. FASEB J. 2008;22:2676-2689.
84. Callewaert F, Venken K, OphoffJ, et al. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-α. FASEB J. 2009;23:232-240.
85. Oz OK, Zerwekh JE, Fisher C, et al. Bone has a sexually dimorphic response to aromatase deficiency. J Bone Miner Res. 2000;15:507-514.
86. Oz OK, Hirasawa G, Lawson J, et al. Bone phenotype of the aromatase deficient mouse. J Steroid Biochem Mol Biol. 2001;79:49-59.
87. Miyaura C, Toda K, Inada M, et al. Sexand age-related response to aromatase deficiency in bone. Biochem Biophys Res Commun. 2001;280:1062-1068.
88. Hewitt SC, Kissling GE, Fieselman KE, Jayes FL, Gerrish KE, Korach KS. Biological and biochemical consequences of global deletion of exon 3 from the ER α gene. FASEB J. 2010;24:4660-4667.
89. Vidal O, Lindberg MK, Hollberg K, et al. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc Natl Acad Sci USA. 2000;97:5474-5479.
90. Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson JA, Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol. 2001;171:229-236.
91. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERβ(-/-) mice. J Clin Invest. 1999;104:895-901.
92. Windahl SH, Hollberg K, Vidal O, Gustafsson JA, Ohlsson C, Andersson G. Female estrogen receptor β-/- mice are partially protected against age-related trabecular bone loss. J Bone Miner Res. 2001;16:1388-1398.
93. Sims NA, Dupont S, Krust A, et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-β in bone remodeling in females but not in males. Bone. 2002;30:18-25.
94. Syed FA, Mödder UI, Fraser DG, et al. Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res. 2005;20:1992-2001.
95. Syed FA, Fraser DG, Monroe DG, Khosla S. Distinct effects of loss of classical estrogen receptor signaling versus complete deletion of estrogen receptor α on bone. Bone. 2011;49:208-216.
96. Syed FA, Fraser DG, Spelsberg TC, et al. Effects of loss of classical estrogen response element signaling on bone in male mice. Endocrinology. 2007;148:1902-1910.
97. Kerkhofs S, Denayer S, Haelens A, Claessens F. Androgen receptor knockout and knock-in mouse models. J Mol Endocrinol. 2009;42:11-17.
98. Matsumoto T, Takeyama K, Sato T, Kato S. Androgen receptor functions from reverse genetic models. J Steroid Biochem Mol Biol. 2003;85:95-99.
99. De Gendt K, Swinnen JV, Saunders PT, et al. A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci USA. 2004;101:1327-1332.
100. Notini AJ, Davey RA, McManus JF, Bate KL, Zajac JD. Genomic actions of the androgen receptor are required for normal male sexual differentiation in a mouse model. JMol Endocrinol. 2005;35:547-555.
101. Pang TP, Clarke MV, Ghasem-Zadeh A, Lee NK, Davey RA, MacLean HE. A physiological role for androgen actions in the absence of androgen receptor DNA binding activity. Mol Cell Endocrinol. 2012;348:189-197.
102. MacLean HE, Chiu WS, Ma C, et al. A floxed allele of the androgen receptor gene causes hyperandrogenization in male mice. Physiol Genomics. 2008;33:133-137.
103. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors α (ERα) and β (ERβ) on mouse reproductive phenotypes. Development. 2000;127:4277-4291.
104. Antal MC, Krust A, Chambon P, Mark M. Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERβ-null mutant. Proc Natl Acad Sci USA. 2008;105:2433-2438.
105. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056-1061.
106. OphoffJ, Callewaert F, Venken K, et al. Physical activity in the androgen receptor knockout mouse: evidence for reversal of androgen deficiency on cancellous bone. Biochem Biophys Res Commun. 2009;378:139-144.
107. Rana K, Fam BC, Clarke MV, Pang TP, Zajac JD, MacLean HE. Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance. Am J Physiol Endocrinol Metab. 2011;301:E767-E778.
108. Raskin K, de Gendt K, Duittoz A, et al. Conditional inactivation of androgen receptor gene in the nervous system: effects on male behavioral and neuroendocrine responses. J Neurosci. 2009;29:4461-4470.
109. Riggs BL, Melton Iii LJ 3rd, Robb RA, et al. Populationbased study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res. 2004;19:1945-1954.
110. Lorentzon M, Swanson C, Andersson N, Mellström D, Ohlsson C. Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res. 2005;20:1334-1341.
111. Vanbillemont G, Lapauw B, Bogaert V, et al. Sex hormone-binding globulin as an independent determinant of cortical bone status in men at the age of peak bone mass. J Clin Endocrinol Metab. 2010;95:1579-1586.
112. Khosla S, Riggs BL, Atkinson EJ, et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res. 2006;21:124-131.
113. Burghardt AJ, Kazakia GJ, Ramachandran S, Link TM, Majumdar S. Ageand gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res. 2010;25:983-993.
114. Dalzell N, Kaptoge S, Morris N, et al. Bone micro-architecture and determinants of strength in the radius and tibia: age-related changes in a population-based study of normal adults measured with high-resolution pQCT. Osteoporos Int. 2009;20:1683-1694.
115. Hansen S, Shanbhogue V, Folkestad L, Nielsen MM, Brixen K. Bone microarchitecture and estimated strength in 499 adult Danish women and men: a cross-sectional, population-based high-resolution peripheral quantitative computed tomographic study on peak bone structure. Calcif Tissue Int. 2014;94:269-281.
116. Kirmani S, Christen D, van Lenthe GH, et al. Bone structure at the distal radius during adolescent growth. J Bone Miner Res. 2009;24:1033-1042.
117. Macdonald HM, Nishiyama KK, Kang J, Hanley DA, Boyd SK. Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study. J Bone Miner Res. 2011;26:50-62.
118. Nishiyama KK, Macdonald HM, Moore SA, Fung T, Boyd SK, McKay HA. Cortical porosity is higher in boys compared with girls at the distal radius and distal tibia during pubertal growth: an HR-pQCT study. J Bone Miner Res. 2012;27:273-282.
119. Walsh JS, Paggiosi MA, Eastell R. Cortical consolidation of the radius and tibia in young men and women. J Clin Endocrinol Metab. 2012;97:3342-3348.
120. Ohlsson C, Darelid A, Nilsson M, Melin J, Mellström D, Lorentzon M. Cortical consolidation due to increased mineralization and endosteal contraction in young adult men: a five-year longitudinal study. J Clin Endocrinol Metab. 2011;96:2262-2269.
121. Riggs BL, Melton LJ, Robb RA, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res. 2008;23:205-214.
122. Lauretani F, Bandinelli S, Griswold ME, et al. Longitudinal changes in BMD and bone geometry in a populationbased study. J Bone Miner Res. 2008;23:400-408.
123. Marshall LM, Lang TF, Lambert LC, et al. Dimensions and volumetric BMD of the proximal femur and their relation to age among older U.S. men. J Bone Miner Res. 2006;21:1197-1206.
124. Parfitt AM, Mathews CH, Villanueva AR, Kleerekoper M, Frame B, Rao DS. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest. 1983;72:1396-1409.
125. Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375:1729-1736.
126. Vandenput L, Lorentzon M, Sundh D, et al. Serum estradiol levels are inversely associated with cortical porosity in older men. J Clin Endocrinol Metab. 2014;99:E1322-E1326.
127. Haentjens P, Johnell O, Kanis JA, et al. Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men. J Bone Miner Res. 2004;19:1933-1944.
128. Hernandez CJ, Beaupré GS, Carter DR. A theoretical analysis of the relative influences of peak BMD, age-related bone loss and menopause on the development of osteoporosis. Osteoporos Int. 2003;14:843-847.
129. Sims NA, Clément-Lacroix P, Minet D, et al. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J Clin Invest. 2003;111:1319-1327.
130. Määttä JA, Büki KG, Ivaska KK, et al. Inactivation of the androgen receptor in bone-forming cells leads to trabecular bone loss in adult female mice. Bonekey Rep. 2013;2:440.
131. Tivesten A, Movérare-Skrtic S, Chagin A, et al. Additive protective effects of estrogen and androgen treatment on trabecular bone in ovariectomized rats. J Bone Miner Res. 2004;19:1833-1839.
132. Smith EP, Specker B, Bachrach BE, et al. Impact on bone of an estrogen receptor-α gene loss of function mutation. J Clin Endocrinol Metab. 2008;93:3088-3096.
133. Vandenput L, Ohlsson C. Estrogens as regulators of bone health in men. Nat Rev Endocrinol. 2009;5:437-443.
134. Bouillon R, Bex M, Vanderschueren D, Boonen S. Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab. 2004;89:6025-6029.
135. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, Vanderschueren D. Evidence from the aged orchidectomized male rat model that 17β-estradiol is a more effective bone-sparing and anabolic agent than 5α-dihydrotestosterone. J Bone Miner Res. 2002;17:2080-2086.
136. Börjesson AE, Farman HH, Engdahl C, et al. The role of activation functions 1 and 2 of estrogen receptor-α for the effects of estradiol and selective estrogen receptor modulators in male mice. J Bone Miner Res. 2013;28:1117-1126.
137. Movérare S, Venken K, Eriksson AL, et al. Differential effects on bone of estrogen receptor α and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci USA. 2003;100:13573-13578.
138. Lindberg MK, Movérare S, Skrtic S, et al. Two different pathways for the maintenance of trabecular bone in adult male mice. J Bone Miner Res. 2002;17:555-562.
139. Lindberg MK, Weihua Z, Andersson N, et al. Estrogen receptor specificity for the effects of estrogen in ovariectomized mice. J Endocrinol. 2002;174:167-178.
140. Harris HA, Albert LM, Leathurby Y, et al. Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 2003;144:4241-4249.
141. Hillisch A, Peters O, Kosemund D, et al. Dissecting physiological roles of estrogen receptor α and β with potent selective ligands from structure-based design. Mol Endocrinol. 2004;18:1599-1609.
142. Ke HZ, Brown TA, Qi H, et al. The role of estrogen receptor-β, in the early age-related bone gain and later agerelated bone loss in female mice. J Musculoskelet Neuronal Interact. 2002;2:479-488.
143. McDougall KE, Perry MJ, Gibson RL, et al. Estrogen-induced osteogenesis in intact female mice lacking ERβ. Am J Physiol Endocrinol Metab. 2002;283:E817-E823.
144. Bord S, Horner A, Beavan S, Compston J. Estrogen receptors α and β are differentially expressed in developing human bone. J Clin Endocrinol Metab. 2001;86:2309-2314.
145. Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. Expression of estrogen receptor β in rat bone. Endocrinology. 1997;138:4509-4512.
146. Seidlova-Wuttke D, Nguyen BT, Wuttke W. Long-term effects of ovariectomy on osteoporosis and obesity in estrogen-receptor-β-deleted mice. Comp Med. 2012;62:8-13.
147. He YX, Liu Z, Pan XH, et al. Deletion of estrogen receptor β accelerates early stage of bone healing in a mouse osteotomy model. Osteoporos Int. 2012;23:377-389.
148. Kamiya Y, Chen J, Xu M, et al. Increased mandibular condylar growth in mice with estrogen receptor β deficiency. J Bone Miner Res. 2013;28:1127-1134.
149. Börjesson AE, Windahl SH, Lagerquist MK, et al. Roles of transactivating functions 1 and 2 of estrogen receptor-α in bone. Proc Natl Acad Sci USA. 2011;108:6288-6293.
150. Lindberg MK, Movérare S, Skrtic S, et al. Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a "ying yang" relationship between ERα and ERβ in mice. Mol Endocrinol. 2003;17:203-208.
151. Nicks KM, Fujita K, Fraser D, et al. Deletion of ERβ in early osteoprogenitor cells leads to a doubling of trabecular bone. In: Proceedings from the American Society for Bone and Mineral Research; October 4-7, 2013; Baltimore, MD. Oral Presentation 1090.
152. Ogawa S, Hosoi T, Shiraki M, et al. Association of estrogen receptor β gene polymorphism with bone mineral density. Biochem Biophys Res Commun. 2000;269:537-541.
153. Lau HH, Ho AY, Luk KD, Kung AW. Estrogen receptor β gene polymorphisms are associated with higher bone mineral density in premenopausal, but not postmenopausal southern Chinese women. Bone. 2002;31:276-281.
154. Shearman AM, Karasik D, Gruenthal KM, et al. Estrogen receptor β polymorphisms are associated with bone mass in women and men: the Framingham Study. J Bone Miner Res. 2004;19:773-781.
155. Scariano JK, Simplicio SG, Montoya GD, Garry PJ, Baumgartner RN. Estrogen receptor β dinucleotide (CA) repeat polymorphism is significantly associated with bone mineral density in postmenopausal women. Calcif Tissue Int. 2004;74:501-508.
156. Geng L, Yao Z, Yang H, Luo J, Han L, Lu Q. Association of CA repeat polymorphism in estrogen receptor β gene with postmenopausal osteoporosis in Chinese. J Genet Genomics. 2007;34:868-876.
157. Mendoza N, Quereda F, Presa J, et al. Estrogen-related genes and postmenopausal osteoporosis risk. Climacteric. 2012;15:587-593.
158. Currò M, Marini H, Alibrandi A, et al. The ESR2 AluI gene polymorphism is associated with bone mineral density in postmenopausal women. J Steroid Biochem Mol Biol. 2011;127:413-417.
159. Honma N, Mori S, Zhou H, et al. Association between estrogen receptor-β dinucleotide repeat polymorphism and incidence of femoral fracture. J Bone Miner Metab. 2013;31:96-101.
160. Zhang L, Choi HJ, Estrada K, et al. Multistage genomewide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet. 2014;23:1923-1933.
161. Koller DL, Zheng HF, Karasik D, et al. Meta-analysis of genome-wide studies identifies WNT16 and ESR1 SNPs associated with bone mineral density in premenopausal women. J Bone Miner Res. 2013;28:547-558.
162. Paternoster L, Lorentzon M, Lehtimaki T, et al. Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure. PLoS Genet. 2013;9:e1003247.
163. Movérare-Skrtic S, Börjesson AE, Farman HH, et al. The estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor α AF-2 is modified. Proc Natl Acad Sci USA. 2014;111:1180-1185.
164. Börjesson AE, Windahl SH, Karimian E, et al. The role of estrogen receptor-α and its activation function-1 for growth plate closure in female mice. Am J Physiol Endocrinol Metab. 2012;302:E1381-E1389.
165. MacLean HE, Moore AJ, Sastra SA, et al. DNA-bindingdependent androgen receptor signaling contributes to gender differences and has physiological actions in males and females. J Endocrinol. 2010;206:93-103.
166. Rochira V, Zirilli L, Madeo B, et al. Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone. Bone. 2007;40:1662-1668.
167. Van Caenegem E, Wierckx K, Taes Y, et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab. 2012;97:2503-2511.
168. Taes Y, Lapauw B, Vandewalle S, et al. Estrogen-specific action on bone geometry and volumetric bone density: longitudinal observations in an adult with complete androgen insensitivity. Bone. 2009;45:392-397.
169. Han TS, Goswami D, Trikudanathan S, Creighton SM, Conway GS. Comparison of bone mineral density and body proportions between women with complete androgen insensitivity syndrome and women with gonadal dysgenesis. Eur J Endocrinol. 2008;159:179-185.
170. Chiang C, Chiu M, Moore AJ, et al. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res. 2009;24:621-631.
171. Notini AJ, McManus JF, Moore A, et al. Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. J Bone Miner Res. 2007;22:347-356.
172. Sinnesael M, Claessens F, Laurent M, et al. Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes. J Bone Miner Res. 2012;27:2535-2543.
173. Konforte D, Shea JL, Kyriakopoulou L, et al. Complex biological pattern of fertility hormones in children and adolescents: a study of healthy children from the CALIPER cohort and establishment of pediatric reference intervals. Clin Chem. 2013;59:1215-1227.
174. Jansson JO, Ekberg S, Isaksson O, Mode A, Gustafsson JA. Imprinting of growth hormone secretion, body growth, and hepatic steroid metabolism by neonatal testosterone. Endocrinology 1985;117:1881-1889.
175. Sims NA, Brennan K, Spaliviero J, Handelsman DJ, Seibel MJ. Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am J Physiol Endocrinol Metab. 2006;290:E456-E462.
176. Aguirre JI, Plotkin LI, Gortazar AR, et al. A novel ligandindependent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. J Biol Chem. 2007;282:25501-25508.
177. Galea GL, Meakin LB, Sugiyama T, et al. Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute downregulation of the Wnt antagonist Sost is mediated by estrogen receptor β. J Biol Chem. 2013;288:9035-9048.
178. Windahl SH, Saxon L, Börjesson AE, et al. Estrogen receptor-α is required for the osteogenic response to mechanical loading in a ligand-independent manner involving its activation function 1 but not 2. J Bone Miner Res. 2013;28:291-301.
179. Almeida M, Iyer S, Martin-Millan M, et al. Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Invest. 2013;123:394-404.
180. Mödder UI, Rudnik V, Liu G, Khosla S, Monroe DG. A DNA binding mutation in estrogen receptor-α leads to suppression of Wnt signaling via β-catenin destabilization in osteoblasts. J Cell Biochem. 2012;113:2248-2255.
181. Almeida M, Martin-Millan M, Ambrogini E, et al. Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα. J Bone Miner Res. 2010;25:769-781.
182. Chokalingam K, Roforth MM, Nicks KM, et al. Examination of ERα signaling pathways in bone of mutant mouse models reveals the importance of ERE-dependent signaling. Endocrinology. 2012;153:5325-5333.
183. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104:719-730.
184. Kousteni S, Chen JR, Bellido T, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science. 2002;298:843-846.
185. Kousteni S, Han L, Chen JR, et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest. 2003;111:1651-1664.
186. Kousteni S, Almeida M, Han L, Bellido T, Jilka RL, Manolagas SC. Induction of osteoblast differentiation by selective activation of kinase-mediated actions of the estrogen receptor. Mol Cell Biol. 2007;27:1516-1530.
187. Movérare S, Dahllund J, Andersson N, et al. Estren is a selective estrogen receptor modulator with transcriptional activity. Mol Pharmacol. 2003;64:1428-1433.
188. Windahl SH, Galien R, Chiusaroli R, et al. Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor. J Clin Invest. 2006;116:2500-2509.
189. Manolagas SC, Jilka RL, Kousteni S, et al. Response to Windahl et al. J Clin Invest. 2006;116:2834.
190. Hewitt SC, Collins J, Grissom S, Hamilton K, Korach KS. Estren behaves as a weak estrogen rather than a nongenomic selective activator in the mouse uterus. Endocrinology. 2006;147:2203-2214.
191. Bartell SM, Han L, Kim HN, et al. Non-nuclear-initiated actions of the estrogen receptor protect cortical bone mass. Mol Endocrinol. 2013;27:649-656.
192. Martin-Millan M, Almeida M, Ambrogini E, et al. The estrogen receptor-α in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010;24:323-334.
193. Heino TJ, Chagin AS, Sävendahl L. The novel estrogen receptor G-protein-coupled receptor 30 is expressed in human bone. J Endocrinol. 2008;197:R1-R6.
194. Windahl SH, Andersson N, Chagin AS, et al. The role of the G protein-coupled receptor GPR30 in the effects of estrogen in ovariectomized mice. Am J Physiol Endocrinol Metab. 2009;296:E490-E496.
195. Mårtensson UE, Salehi SA, Windahl S, et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology. 2009;150:687-698.
196. Ford J, Hajibeigi A, Long M, et al. GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice. J Bone Miner Res. 2011;26:298-307.
197. Chagin AS, Sävendahl L. GPR30 estrogen receptor expression in the growth plate declines as puberty progresses. J Clin Endocrinol Metab. 2007;92:4873-4877.
198. Drake MT, McCready LK, Hoey KA, Atkinson EJ, Khosla S. Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women. J Clin Endocrinol Metab. 2010;95:5063-5068.
199. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell. 2006;125:247-260.
200. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M. Folliclestimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA. 2006;103:14925-14930.
201. Zhu LL, Blair H, Cao J, et al. Blocking antibody to the β-subunit of FSH prevents bone loss by inhibiting bone resorption and stimulating bone synthesis. Proc Natl Acad Sci USA. 2012;109:14574-14579.
202. Geng W, Yan X, Du H, Cui J, Li L, Chen F. Immunization with FSHβ fusion protein antigen prevents bone loss in a rat ovariectomy-induced osteoporosis model. Biochem Biophys Res Commun. 2013;434:280-286.
203. Yarram SJ, Perry MJ, Christopher TJ, et al. Luteinizing hormone receptor knockout (LuRKO) mice and transgenic human chorionic gonadotropin (hCG)-overexpressing mice (hCG αβ+) have bone phenotypes. Endocrinology. 2003;144:3555-3564.
204. Seibel MJ, Dunstan CR, Zhou H, Allan CM, Handelsman DJ. Sex steroids, not FSH, influence bone mass. Cell. 2006; 127:1079; author reply 1080-1081.
205. Gao J, Tiwari-Pandey R, Samadfam R, et al. Altered ovarian function affects skeletal homeostasis independent of the action of follicle-stimulating hormone. Endocrinology. 2007;148:2613-2621.
206. Rouach V, Katzburg S, Koch Y, Stern N, Somjen D. Bone loss in ovariectomized rats: dominant role for estrogen but apparently not for FSH. J Cell Biochem. 2011;112:128-137.
207. Allan CM, Kalak R, Dunstan CR, et al. Follicle-stimulating hormone increases bone mass in female mice. Proc Natl Acad Sci USA. 2010;107:22629-22634.
208. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369:1011-1022.
209. Uihlein AV, Finkelstein JS, Lee H, Leder BZ. FSH suppression does not affect bone turnover in eugonadal men. J Clin Endocrinol Metab. 2014;99:2510-2515.
210. Almeida M, Han L, Martin-Millan M, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007;282:27285-27297.
211. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-137.
212. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell. 2007;130:811-823.
213. Seitz S, Keller J, Schilling AF, et al. Pharmacological estrogen administration causes a FSH-independent osteo-anabolic effect requiring ER α in osteoblasts. PLoS One. 2012; 7:e50301.
214. Krum SA, Miranda-Carboni GA, Hauschka PV, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J. 2008;27:535-545.
215. Michael H, Härkönen PL, Väänänen HK, Hentunen TA. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res. 2005;20:2224-2232.
216. Turner AG, Notini AJ, Chiu WS, et al. Androgen receptor expression and function in osteoclasts. Open Physiol J. 2008;1:28-33.
217. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17:1235-1241.
218. Manolagas SC, O'Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2013;9:699-712.
219. Määttä JA, Büki KG, Gu G, et al. Inactivation of estrogen receptor α in bone-forming cells induces bone loss in female mice. FASEB J. 2013;27:478-488.
220. Windahl SH, Börjesson AE, Farman HH, et al. Estrogen receptor-α in osteocytes is important for trabecular bone formation in male mice. Proc Natl Acad Sci USA. 2013;110:2294-2299.
221. Melville KM, Kelly NH, Khan SA, et al. Female mice lacking estrogen receptor-α in osteoblasts have compromised bone mass and strength. J Bone Miner Res. 2014;29:370-379.
222. Kondoh S, Inoue K, Igarashi K, et al. Estrogen receptor α in osteocytes regulates trabecular bone formation in female mice. Bone. 2014;60:68-77.
223. Ucer S, Warren A, Bartell S, et al. Unlike the estrogen receptor α, the androgen receptor in osteoblast progenitors is dispensable for optimal cortical bone accrual. In: Proceedings from the American Society for Bone and Mineral Research; October 4-7, 2013; Baltimore, MD. Presentation FR0446.
224. Wiren KM, Zhang XW, Toombs AR, et al. Targeted overexpression of androgen receptor in osteoblasts: unexpected complex bone phenotype in growing animals. Endocrinology. 2004;145:3507-3522.
225. Wiren KM, Semirale AA, Zhang XW, et al. Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton. Bone. 2008;43:440-451.
226. Börjesson AE, Lagerquist MK, Windahl SH, Ohlsson C. The role of estrogen receptor α in the regulation of bone and growth plate cartilage. Cell Mol Life Sci. 2013;70:4023-4037.
227. Vanderschueren D, Boonen S, Ederveen AG, et al. Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model. Bone. 2000;27:611-617.
228. Chagin AS, Lindberg MK, Andersson N, et al. Estrogen receptor-β inhibits skeletal growth and has the capacity to mediate growth plate fusion in female mice. J Bone Miner Res. 2004;19:72-77.
229. Börjesson AE, Lagerquist MK, Liu C, et al. The role of estrogen receptor α in growth plate cartilage for longitudinal bone growth. J Bone Miner Res. 2010;25:2690-2700.
230. Russell PK, Clarke MV, Skinner JP, Pang TP, Zajac JD, Davey RA. Identification of gene pathways altered by deletion of the androgen receptor specifically in mineralizing osteoblasts and osteocytes in mice. J Mol Endocrinol. 2012;49:1-10.
231. Wiren KM, Semirale AA, Hashimoto JG, Zhang XW. Signaling pathways implicated in androgen regulation of endocortical bone. Bone. 2010;46:710-723.
232. Fujita K, Roforth MM, Demaray S, et al. Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. J Clin Endocrinol Metab. 2014;99:E81-E88.
233. Krum SA. Direct transcriptional targets of sex steroid hormones in bone. J Cell Biochem. 2011;112:401-408.
234. Zaman G, Saxon LK, Sunters A, et al. Loading-related regulation of gene expression in bone in the contexts of estrogen deficiency, lack of estrogen receptor α and disuse. Bone. 2010;46:628-642.
235. Garcia AJ, Tom C, Guemes M, et al. ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis. J Bone Miner Res. 2013;28:283-290.
236. Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M. Unique ERα cistromes control cell type-specific gene regulation. Mol Endocrinol. 2008;22:2393-2406.
237. Miranda-Carboni GA, Guemes M, Bailey S, et al. GATA4 regulates estrogen receptor-α-mediated osteoblast transcription. Mol Endocrinol. 2011;25:1126-1136.
238. Güemes M, Garcia AJ, Rigueur D, et al. GATA4 is essential for bone mineralization via ERα and TGFβ/BMP pathways [published online June 16, 2014]. J Bone Miner Res. doi:10.1002/jbmr.2296.
239. Monroe DG, Secreto FJ, Hawse JR, Subramaniam M, Khosla S, Spelsberg TC. Estrogen receptor isoform-specific regulation of the retinoblastoma-binding protein 1 (RBBP1) gene: roles of AF1 and enhancer elements. J Biol Chem. 2006;281:28596-28604.
240. Hawse JR, Subramaniam M, Monroe DG, et al. Estrogen receptor β isoform-specific induction of transforming growth factor β-inducible early gene-1 in human osteoblast cells: an essential role for the activation function 1 domain. Mol Endocrinol. 2008;22:1579-1595.
241. Subramaniam M, Hawse JR, Bruinsma ES, et al. TGFβ inducible early gene-1 directly binds to, and represses, the OPG promoter in osteoblasts. Biochem Biophys Res Commun. 2010;392:72-76.
242. Monroe DG, Hawse JR, Subramaniam M, Spelsberg TC. Retinoblastoma binding protein-1 (RBP1) is a Runx2 coactivator and promotes osteoblastic differentiation. BMC Musculoskelet Disord. 2010;11:104.
243. Cicek M, Vrabel A, Sturchio C, et al. TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways. PLoS One. 2011;6:e17522.
244. Hawse JR, Cicek M, Grygo SB, et al. TIEG1/KLF10 modulates Runx2 expression and activity in osteoblasts. PLoS One. 2011;6:e19429.
245. Glait-Santar C, Benayahu D. Regulation of SVEP1 gene expression by 17β-estradiol and TNFα in pre-osteoblastic and mammary adenocarcinoma cells. J Steroid Biochem Mol Biol. 2012;130:36-44.
246. Denger S, Bähr-Ivacevic T, Brand H, et al. Transcriptome profiling of estrogen-regulated genes in human primary osteoblasts reveals an osteoblast-specific regulation of the insulin-like growth factor binding protein 4 gene. Mol Endocrinol. 2008;22:361-379.
247. Lambertini E, Tavanti E, Torreggiani E, Penolazzi L, Gambari R, Piva R. ERα and AP-1 interact in vivo with a specific sequence of the F promoter of the human ERα gene in osteoblasts. J Cell Physiol. 2008;216:101-110.
248. Bord S, Ireland DC, Beavan SR, Compston JE. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone. 2003;32:136-141.
249. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC. Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERα or ERβ. J Cell Biochem. 2003;90:315-326.
250. Pederson L, Kremer M, Judd J, et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci USA. 1999;96:505-510.
251. Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol. 2009;23:1203-1214.
252. Miki Y, Suzuki T, Hatori M, et al. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2007;40:876-887.
253. Ohlsson C, Mohan S, Sjögren K, et al. The role of liverderived insulin-like growth factor-I. Endocr Rev. 2009;30:494-535.
254. Olson LE, Ohlsson C, Mohan S. The role of GH/IGF-I-mediated mechanisms in sex differences in cortical bone size in mice. Calcif Tissue Int. 2011;88:1-8.
255. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29:535-559.
256. Courtland HW, DeMambro V, Maynard J, et al. Sex-specific regulation of body size and bone slenderness by the acid labile subunit. J Bone Miner Res. 2010;25:2059-2068.
257. Mohan S, Richman C, Guo R, et al. Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms. Endocrinology. 2003;144:929-936.
258. Chang W, Parra M, Centrella M, McCarthy TL. Interactions between CCAAT enhancer binding protein δ and estrogen receptor α control insulin-like growth factor I (igf1) and estrogen receptor-dependent gene expression in osteoblasts. Gene. 2005;345:225-235.
259. Gori F, Hofbauer LC, Conover CA, Khosla S. Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology. 1999;140:5579-5586.
260. Kasperk C, Fitzsimmons R, Strong D, et al. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab. 1990;71:1322-1329.
261. Kasperk CH, Faehling K, Börcsök I, Ziegler R. Effects of androgens on subpopulations of the human osteosarcoma cell line SaOS2. Calcif Tissue Int. 1996;58:376-382.
262. Bolamperti S, Mrak E, Moro G, et al. 17β-Estradiol positively modulates growth hormone signaling through the reduction of SOCS2 negative feedback in human osteoblasts. Bone. 2013;55:84-92.
263. Sanchez-Cardenas C, Fontanaud P, He Z, et al. Pituitary growth hormone network responses are sexually dimorphic and regulated by gonadal steroids in adulthood. Proc Natl Acad Sci USA. 2010;107:21878-21883.
264. Singhal V, Goh BC, Bouxsein ML, Faugere MC, DiGirolamo DJ. Osteoblast-restricted disruption of the growth hormone receptor in mice results in sexually dimorphic skeletal phenotypes. Bone Res. 2013;1:85-97.
265. Venken K, Schuit F, Van Lommel L, et al. Growth without growth hormone receptor: estradiol is a major growth hormone-independent regulator of hepatic IGF-I synthesis. J Bone Miner Res. 2005;20:2138-2149.
266. Govoni KE, Wergedal JE, Chadwick RB, Srivastava AK, Mohan S. Prepubertal OVX increases IGF-I expression and bone accretion in C57BL/6J mice. Am J Physiol Endocrinol Metab. 2008;295:E1172-E1180.
267. Callewaert F, Sinnesael M, Gielen E, Boonen S, Vanderschueren D. Skeletal sexual dimorphism: relative contribution of sex steroids, GH-IGF1, and mechanical loading. J Endocrinol. 2010;207:127-134.
268. Vanderschueren D, Venken K, OphoffJ, Bouillon R, Boonen S. Clinical review: sex steroids and the periosteum-reconsidering the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab. 2006;91:378-382.
269. Vandenput L, Sjögren K, Svensson J, Ohlsson C. The role of IGF-1 for fracture risk in men. Front Endocrinol (Lausanne). 2012;3:51.
270. Szulc P, Joly-Pharaboz MO, Marchand F, Delmas PD. Insulin-like growth factor I is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study. Calcif Tissue Int. 2004;74:322-329.
271. Boonen S, Pye SR, O'Neill TW, et al. Influence of bone remodelling rate on quantitative ultrasound parameters at the calcaneus and DXA BMDa of the hip and spine in middle-aged and elderly European men: the European Male Ageing Study (EMAS). Eur J Endocrinol. 2011;165:977-986.
272. Ohlsson C, Mellström D, Carlzon D, et al. Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J Bone Miner Res. 2011;26:865-872.
273. Lapauw B, T'Sjoen G, Mahmoud A, Kaufman JM, Ruige JB. Short-term aromatase inhibition: effects on glucose metabolism and serum leptin levels in young and elderly men. Eur J Endocrinol. 2009;160:397-402.
274. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009;94:4785-4792.
275. Leder BZ, Finkelstein JS. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int. 2005;16:1487-1494.
276. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106:1553-1560.
277. Bouillon R, Van Schoor NM, Gielen E, et al. Optimal vitamin D status: a critical analysis on the basis of evidencebased medicine. J Clin Endocrinol Metab. 2013;98: E1283-E1304.
278. Curtis JR, Ewing SK, Bauer DC, et al. Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study. J Clin Endocrinol Metab. 2012;97:1937-1944.
279. Vanderschueren D, Pye SR, O'Neill TW, et al. Active vitamin D (1,25-dihydroxyvitamin D) and bone health in middle-aged and elderly men: the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2013;98:995-1005.
280. Ensrud KE, Taylor BC, Paudel ML, et al. Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men. J Clin Endocrinol Metab. 2009;94:2773-2780.
281. Cauley JA, Parimi N, Ensrud KE, et al. Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. J Bone Miner Res. 2010;25:545-553.
282. Barrett-Connor E, Laughlin GA, Li H, et al. The association of concurrent vitamin D and sex hormone deficiency with bone loss and fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2012;27:2306-2313.
283. Wehr E, Pilz S, Boehm BO, März W, Obermayer-Pietsch B. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf). 2010;73:243-248.
284. Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol. 2012;166:77-85.
285. Pilz S, Frisch S, Koertke H, et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res. 2011;43:223-225.
286. Somjen D, Katzburg S, Stern N, et al. 25 Hydroxy-vitamin D(3)-1α hydroxylase expression and activity in cultured human osteoblasts and their modulation by parathyroid hormone, estrogenic compounds and dihydrotestosterone. J Steroid Biochem Mol Biol. 2007;107:238-244.
287. Hsu YJ, Dimke H, Schoeber JP, et al. Testosterone increases urinary calcium excretion and inhibits expression of renal calcium transport proteins. Kidney Int. 2010;77:601-608.
288. Meng J, Ohlsson C, Laughlin GA, et al. Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study. Kidney Int. 2010;78:415-422.
289. Frenkel B, Hong A, Baniwal SK, et al. Regulation of adult bone turnover by sex steroids. J Cell Physiol. 2010;224:305-310.
290. Khalid O, Baniwal SK, Purcell DJ, et al. Modulation of Runx2 activity by estrogen receptor-α: implications for osteoporosis and breast cancer. Endocrinology. 2008;149:5984-5995.
291. McCarthy TL, Chang WZ, Liu Y, Centrella M. Runx2 integrates estrogen activity in osteoblasts. J Biol Chem. 2003;278:43121-43129.
292. Kawate H, Wu Y, Ohnaka K, Takayanagi R. Mutual transactivational repression of Runx2 and the androgen receptor by an impairment of their normal compartmentalization. J Steroid Biochem Mol Biol. 2007;105:46-56.
293. Jeong JH, Jung YK, Kim HJ, et al. The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of Runx2 in skeletal tissues. Mol Cell Biol. 2010;30:2365-2375.
294. Maruyama Z, Yoshida CA, Furuichi T, et al. Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Dev Dyn. 2007;236:1876-1890.
295. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33:747-783.
296. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-869.
297. Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt/β- catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010;30:3071-3085.
298. Javaheri B, Stern AR, Lara N, et al. Deletion of a single β-catenin allele in osteocytes abolishes the bone anabolic response to loading. J Bone Miner Res. 2014;29:705-715.
299. Noh T, Gabet Y, Cogan J, et al. Lef1 haploinsufficient mice display a low turnover and low bone mass phenotype in a genderand age-specific manner. PLoS One. 2009;4: e5438.
300. Yao W, Cheng Z, Shahnazari M, Dai W, Johnson ML, Lane NE. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res. 2010;25:190-199.
301. Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M. Mef2c deletion in osteocytes results in increased bone mass. J Bone Miner Res. 2012;27:360-373.
302. Saxon LK, Jackson BF, Sugiyama T, Lanyon LE, Price JS. Analysis of multiple bone responses to graded strains above functional levels, and to disuse, in mice in vivo show that the human Lrp5 G171V high bone mass mutation increases the osteogenic response to loading but that lack of Lrp5 activity reduces it. Bone. 2011;49:184-193.
303. Liu XH, Kirschenbaum A, Yao S, Levine AC. Androgens promote preosteoblast differentiation via activation of the canonical Wnt signaling pathway. Ann NY Acad Sci. 2007;1116:423-431.
304. Jastrzebski S, Kalinowski J, Stolina M, et al. Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J Bone Miner Res. 2013;28:618-626.
305. Kim BJ, Bae SJ, Lee SY, et al. TNF-α mediates the stimulation of sclerostin expression in an estrogen-deficient condition. Biochem Biophys Res Commun. 2012;424:170-175.
306. Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab. 2013;98:3873-3883.
307. Roforth MM, Fujita K, McGregor UI, et al. Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone. 2014;59:1-6.
308. Mödder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26:373-379.
309. Amrein K, Amrein S, Drexler C, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012;97:148-154.
310. Szulc P, Bertholon C, Borel O, Marchand F, Chapurlat R. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res. 2013;28:855-864.
311. Szulc P, Boutroy S, Vilayphiou N, et al. Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res. 2013;28:1760-1770.
312. Lapauw B, Vandewalle S, Taes Y, et al. Serum sclerostin levels in men with idiopathic osteoporosis. Eur J Endocrinol. 2013;168:615-620.
313. Kuipers AL, Zhang Y, Yu S, et al. Relative influence of heritability, environment and genetics on serum sclerostin. Osteoporos Int. 2014;25:905-912.
314. Kirmani S, Amin S, McCready LK, et al. Sclerostin levels during growth in children. Osteoporos Int. 2012;23:1123-1130.
315. Mödder UI, Clowes JA, Hoey K, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011;26:27-34.
316. Lee K, Jessop H, Suswillo R, Zaman G, Lanyon L. Endocrinology: bone adaptation requires oestrogen receptor-α. Nature. 2003;424:389.
317. Saxon LK, Galea G, Meakin L, Price J, Lanyon LE. Estrogen receptors α and β have different gender-dependent effects on the adaptive responses to load bearing in cancellous and cortical bone. Endocrinology. 2012;153:2254-2266.
318. Sugiyama T, Galea GL, Lanyon LE, Price JS. Mechanical loading-related bone gain is enhanced by tamoxifen but unaffected by fulvestrant in female mice. Endocrinology. 2010;151:5582-5590.
319. Sample SJ, Racette MA, Hao Z, Thomas CF, Behan M, Muir P. Functional adaptation in female rats: the role of estrogen signaling. PLoS One. 2012;7:e43215.
320. Saxon LK, Turner CH. Low-dose estrogen treatment suppresses periosteal bone formation in response to mechanical loading. Bone. 2006;39:1261-1267.
321. Järvinen TL, Kannus P, Pajamäki I, et al. Estrogen deposits extra mineral into bones of female rats in puberty, but simultaneously seems to suppress the responsiveness of female skeleton to mechanical loading. Bone. 2003;32:642-651.
322. Jagger CJ, Chow JW, Chambers TJ. Estrogen suppresses activation but enhances formation phase of osteogenic response to mechanical stimulation in rat bone. J Clin Invest. 1996;98:2351-2357.
323. Tromp AM, Bravenboer N, Tanck E, et al. Additional weight bearing during exercise and estrogen in the rat: the effect on bone mass, turnover, and structure. Calcif Tissue Int. 2006;79:404-415.
324. Pajamäki I, Sievänen H, Kannus P, Jokihaara J, Vuohelainen T, Järvinen TL. Skeletal effects of estrogen and mechanical loading are structurally distinct. Bone. 2008;43:748-757.
325. Callewaert F, Bakker A, Schrooten J, et al. Androgen receptor disruption increases the osteogenic response to mechanical loading in male mice. J Bone Miner Res. 2010;25:124-131.
326. Armstrong VJ, Muzylak M, Sunters A, et al. Wnt/β-catenin signaling is a component of osteoblastic bone cell early responses to load-bearing and requires estrogen receptor α. J Biol Chem. 2007;282:20715-20727.
327. Sunters A, Armstrong VJ, Zaman G, et al. Mechano-transduction in osteoblastic cells involves strain-regulated estrogen receptor α-mediated control of insulin-like growth factor (IGF) I receptor sensitivity to ambient IGF, leading to phosphatidylinositol 3-kinase/AKT-dependent Wnt/LRP5 receptor-independent activation of β-catenin signaling. J Biol Chem. 2010;285:8743-8758.
328. Meakin LB, Sugiyama T, Galea GL, Browne WJ, Lanyon LE, Price JS. Male mice housed in groups engage in frequent fighting and show a lower response to additional bone loading than females or individually housed males that do not fight. Bone. 2013;54:113-117.
329. Eisenmann JC, Wickel EE, Kelly SA, Middleton KM, Garland T Jr. Day-to-day variability in voluntary wheel running among genetically differentiated lines of mice that vary in activity level. Eur J Appl Physiol. 2009;106:613-619.
330. Carrera O, Cerrato M, Vazquez R, Sineiro C, Gutierrez E. Gender dimorphic effects of voluntary running in laboratory rats depends on maturational status. Q J Exp Psychol (Hove). 2011;64:823-832.
331. Zaman G, Jessop HL, Muzylak M, et al. Osteocytes use estrogen receptor α to respond to strain but their ERα content is regulated by estrogen. J Bone Miner Res. 2006;21:1297-1306.
332. Ren J, Wang XH, Wang GC, Wu JH. 17β Estradiol regulation of connexin 43-based gap junction and mechanosensitivity through classical estrogen receptor pathway in osteocyte-like MLO-Y4 cells. Bone. 2013;53:587-596.
333. Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performanceenhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35:341-375.
334. Dubois V, Laurent M, Boonen S, Vanderschueren D, Claessens F. Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci. 2012;69:1651-1667.
335. Velders M, Diel P. How sex hormones promote skeletal muscle regeneration. Sports Med. 2013;43:1089-1100.
336. Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA. 2012;307:931-939.
337. Borst SE, Yarrow JF, Conover CF, et al. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2014;306:E433-E442.
338. Lebrasseur NK, Achenbach SJ, Melton LJ 3rd, Amin S, Khosla S. Skeletal muscle mass is associated with bone geometry and microstructure and serum insulin-like growth factor binding protein-2 levels in adult women and men. J Bone Miner Res. 2012;27:2159-2169.
339. OphoffJ, Van Proeyen K, Callewaert F, et al. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology. 2009;150:3558-3566.
340. Chambon C, Duteil D, Vignaud A, et al. Myocytic androgen receptor controls the strength but not the mass of limb muscles. Proc Natl Acad Sci USA. 2010;107:14327-14332.
341. Dubois V, Laurent MR, Sinnesael M, et al. A satellite cellspecific knockout of the androgen receptor reveals myostatin as a direct androgen target in skeletal muscle. FASEB J. 2014;28:2979-2994.
342. Verschueren S, Gielen E, O'Neill TW, et al. Sarcopenia and its relationship with bone mineral density in middleaged and elderly European men. Osteoporos Int. 2013;24:87-98.
343. Wimalawansa SM, Chapa MT, Wei JN, Westlund KN, Quast MJ, Wimalawansa SJ. Reversal of weightlessnessinduced musculoskeletal losses with androgens: quantification by MRI. J Appl Physiol (1985). 1999;86:1841-1846.
344. Cardozo CP, Qin W, Peng Y, et al. Nandrolone slows hindlimb bone loss in a rat model of bone loss due to denervation. Ann NY Acad Sci. 2010;1192:303-306.
345. Yarrow JF, Conover CF, Beggs LA, et al. Testosterone dose dependently prevents bone and muscle loss in rodents after spinal cord injury. J Neurotrauma. 2014;31:834-845.
346. Libouban H, Blouin S, Moreau MF, Baslé MF, Audran M, Chappard D. Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: densitometric, histomorphometric and microtomographic studies. Micron. 2008;39:998-1007.
347. Maggi A, Ciana P, Belcredito S, Vegeto E. Estrogens in the nervous system: mechanisms and nonreproductive functions. Annu Rev Physiol. 2004;66:291-313.
348. Burt-Pichat B, Lafage-Proust MH, Duboeuf F, et al. Dramatic decrease of innervation density in bone after ovariectomy. Endocrinology. 2005;146:503-510.
349. Bouxsein ML, Devlin MJ, Glatt V, Dhillon H, Pierroz DD Ferrari SL. Mice lacking β-adrenergic receptors have increased bone mass but are not protected from deleterious skeletal effects of ovariectomy. Endocrinology. 2009;150:144-152.
350. Farr JN, Charkoudian N, Barnes JN, et al. Relationship of sympathetic activity to bone microstructure, turnover, and plasma osteopontin levels in women. J Clin Endocrinol Metab. 2012;97:4219-4227.
351. Ohlsson C, Engdahl C, Börjesson AE, et al. Estrogen receptor-α expression in neuronal cells affects bone mass. Proc Natl Acad Sci USA. 2012;109:983-988.
352. Farman HH, Windahl SH, Clegg DJ, et al. Mice lacking estrogen receptor α in hypothalamic pro-opiomelanocortin (POMC) neurons display enhanced estrogenic response on bone mass. In: Proceedings from the American Society for Bone and Mineral Research; October 4-7, 2013; Baltimore, MD. Presentation FR0445.
353. Reid IR. Fat and bone. Arch Biochem Biophys. 2010;503:20-27.
354. Ng AC, Melton LJ 3rd, Atkinson EJ, et al. Relationship of adiposity to bone volumetric density and microstructure in men and women across the adult lifespan. Bone. 2013;55:119-125.
355. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39-52.
356. Kenny AM, Kleppinger A, Annis K, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58:1134-1143.
357. Bouloux PM, Legros JJ, Elbers JM, et al. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebocontrolled, dose-ranging study. Aging Male. 2013;16:38-47.
358. Sinnesael M, Callewaert F, Morreels M, et al. 7α-Methyl-19-nortestosterone vs. testosterone implants for hypogonadal osteoporosis: a preclinical study in the aged male orchidectomized rat model. Int J Androl. 2011;34:e601-e611.
359. Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2:153-161.
360. Huang CK, Lai KP, Luo J, et al. Loss of androgen receptor promotes adipogenesis but suppresses osteogenesis in bone marrow stromal cells. Stem Cell Res. 2013;11:938-950.
361. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci USA. 2000;97:12729-12734.
362. Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S. Late onset of obesity in male androgen receptordeficient (AR KO) mice. Biochem Biophys Res Commun. 2003;300:167-171.
363. Ohlsson C, Hellberg N, Parini P, et al. Obesity and disturbed lipoprotein profile in estrogen receptor-α-deficient male mice. Biochem Biophys Res Commun. 2000;278:640-645.
364. McInnes KJ, Smith LB, Hunger NI, Saunders PT, Andrew R, Walker BR. Deletion of the androgen receptor in adipose tissue in male mice elevates retinol binding protein 4 and reveals independent effects on visceral fat mass and on glucose homeostasis. Diabetes. 2012;61:1072-1081.
365. Pacifici R. Role of T cells in ovariectomy induced bone loss-revisited. J Bone Miner Res. 2012;27:231-239.
366. Bellido T, Jilka RL, Boyce BF, et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995;95:2886-2895.
367. Onal M, Xiong J, Chen X, et al. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem. 2012;287:29851-29860.
368. Altuwaijri S, Chuang KH, Lai KP, et al. Susceptibility to autoimmunity and B cell resistance to apoptosis in mice lacking androgen receptor in B cells. Mol Endocrinol. 2009;23:444-453.
369. Lélu K, Laffont S, Delpy L, et al. Estrogen receptor α signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. J Immunol. 2011;187:2386-2393.
370. Kuchuk NO, van Schoor NM, Pluijm SM, Smit JH, de Ronde W, Lips P. The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. Clin Endocrinol (Oxf). 2007;67:295-303.
371. Araujo AB, Travison TG, Leder BZ, McKinlay JB. Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab. 2008;93:2135-2141.
372. Paller CJ, Shiels MS, Rohrmann S, et al. Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men. Clin Endocrinol (Oxf). 2009;70:26-34.
373. Woo J, Kwok T, Leung JC, Ohlsson C, Vandenput L, Leung PC. Sex steroids and bone health in older Chinese men. Osteoporos Int. 2012;23:1553-1562.
374. Laurent M, Antonio L, Sinnesael M, et al. Androgens and estrogens in skeletal sexual dimorphism. Asian J Androl. 2014;16:213-222.
375. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86:3555-3561.
376. Gennari L, Merlotti D, Martini G, et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab. 2003;88:5327-5333.
377. Van Pottelbergh I, Goemaere S, Kaufman JM. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab. 2003;88:3075-3081.
378. Cauley JA, Ewing SK, Taylor BC, et al. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density-the Osteoporotic Fractures in Men Study. J Clin Endocrinol Metab. 2010;95:4314-4323.
379. Khosla S, Melton LJ 3rd, Robb RA, et al. Relationship of volumetric BMD and structural parameters at different skeletal sites to sex steroid levels in men. J Bone Miner Res. 2005;20:730-740.
380. Ward KA, Pye SR, Adams JE, et al. Influence of age and sex steroids on bone density and geometry in middle-aged and elderly European men. Osteoporos Int. 2011;22:1513-1523.
381. Khosla S, Melton LJ 3rd, Achenbach SJ, Oberg AL, Riggs BL. Hormonal and biochemical determinants of trabecular microstructure at the ultradistal radius in women and men. J Clin Endocrinol Metab. 2006;91:885-891.
382. Argoud T, Boutroy S, Claustrat B, Chapurlat R, Szulc P. Association between sex steroid levels and bone microarchitecture in men: the STRAMBO study. J Clin Endocrinol Metab. 2014;99:1400-1410.
383. Szulc P, Uusi-Rasi K, Claustrat B, Marchand F, Beck TJ, Delmas PD. Role of sex steroids in the regulation of bone morphology in men. The MINOS study. Osteoporos Int. 2004;15:909-917.
384. Travison TG, Araujo AB, Beck TJ, et al. Relation between serum testosterone, serum estradiol, sex hormone-binding globulin, and geometrical measures of adult male proximal femur strength. J Clin Endocrinol Metab. 2009;94:853-860.
385. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
386. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004;22:2546-2553.
387. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int. 2009;104:800-805.
388. Mueller A, Zollver H, Kronawitter D, et al. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist. Exp Clin Endocrinol Diabetes. 2011;119:95-100.
389. Ruetsche AG, Kneubuehl R, Birkhaeuser MH, Lippuner K. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a crosssectional study. Osteoporos Int. 2005;16:791-798.
390. Gennari L, Masi L, Merlotti D, et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab. 2004;89:2803-2810.
391. Eriksson AL, Lorentzon M, Vandenput L, et al. Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J Clin Endocrinol Metab. 2009;94:1033-1041.
392. Limer KL, Pye SR, Thomson W, et al. Genetic variation in sex hormone genes influences heel ultrasound parameters in middle-aged and elderly men: results from the European Male Aging Study (EMAS). J Bone Miner Res. 2009;24:314-323.
393. Huhtaniemi IT, Pye SR, Limer KL, et al. Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats. J Clin Endocrinol Metab. 2009;94:277-284.
394. Rivadeneira F, Styrkársdottir U, Estrada K, et al. Twenty bone-mineral-density loci identified by large-scale metaanalysis of genome-wide association studies. Nat Genet. 2009;41:1199-1206.
395. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358:2355-2365.
396. Holliday KL, Pye SR, Thomson W, et al. The ESR1 (6q25) locus is associated with calcaneal ultrasound parameters and radial volumetric bone mineral density in European men. PLoS One. 2011;6:e22037.
397. Adler RA. Management of osteoporosis in men on androgen deprivation therapy. Maturitas. 2011;68:143-147.
398. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841-3846.
399. Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184:1316-1321.
400. Jankowski CM, Gozansky WS, Kittelson JM, Van Pelt RE, Schwartz RS, Kohrt WM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab. 2008;93:4767-4773.
401. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647-1659.
402. Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT. Dehydroepiandrosterone replacement therapy in older adults: 1-and 2-y effects on bone. Am J Clin Nutr. 2009;89:1459-1467.
403. von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int. 2008;19:699-707.
404. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003;88:204-210.
405. Yu E, Taylor A, Wulcyzn K, et al. Hypogonadism with estrogen removal (HER): differential effects of androgens and estrogens on bone microarchitecture in adult men. J Bone Miner Res. 2012;27:S66.
406. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010;95:3-10.
407. Barrett-Connor E, Mueller JE, von Mühlen DG, Laughlin GA, Schneider DL, Sartoris DJ. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2000;85:219-223.
408. Bjørnerem A, Ahmed LA, Joakimsen RM, et al. A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromso Study. Eur J Endocrinol. 2007;157:119-125.
409. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters and osteoporotic fractures in elderly men. J Bone Miner Res. 2000;15:1405-1411.
410. Goderie-Plomp HW, van der Klift M, de Ronde W, Hofman A, de Jong FH, Pols HA. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab. 2004;89:3261-3269.
411. Legrand E, Hedde C, Gallois Y, et al. Osteoporosis in men: a potential role for the sex hormone binding globulin. Bone. 2001;29:90-95.
412. Lormeau C, Soudan B, d'Herbomez M, Pigny P, Duquesnoy B, Cortet B. Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis. Bone. 2004;34:933-939.
413. Mellström D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res. 2006;21:529-535.
414. Roddam AW, Appleby P, Neale R, et al. Association between endogenous plasma hormone concentrations and fracture risk in men and women: the EPIC-Oxford prospective cohort study. J Bone Miner Metab. 2009;27:485-493.
415. Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Challenges to the measurement of estradiol: an Endocrine Society position statement. J Clin Endocrinol Metab. 2013;98:1376-1387.
416. Amin S, Zhang Y, Felson DT, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med. 2006;119:426-433.
417. Mellström D, Vandenput L, Mallmin H, et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res. 2008;23:1552-1560.
418. LeBlanc ES, Nielson CM, Marshall LM, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94:3337-3346.
419. Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006;91:3908-3915.
420. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85:3276-3282.
421. Wu FC, Tajar A, Beynon JM, et al. Identification of lateonset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-135.
422. Tajar A, Huhtaniemi IT, O'Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97:1508-1516.
423. Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab. 2007;92:3470-3475.
424. Meriggiola MC, Armillotta F, Costantino A, et al. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. J Sex Med. 2008;5:2442-2453.
425. Van Pottelbergh I, Lumbroso S, Goemaere S, Sultan C, Kaufman JM. Lack of influence of the androgen receptor gene CAG-repeat polymorphism on sex steroid status and bone metabolism in elderly men. Clin Endocrinol (Oxf). 2001;55:659-666.
426. Szulc P, Kaufman JM, Delmas PD. Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int. 2007;18:1451-1461.
427. Meier C, Nguyen TV, Handelsman DJ, et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168:47-54.
428. Orwoll E, Lambert LC, Marshall LM, et al. Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med. 2006;166:2124-2131.
429. Drake MT, Murad MH, Mauck KF, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97:1861-1870.
430. Hyde Z, Flicker L, Almeida OP, et al. Low free testosterone predicts frailty in older men: the Health in Men Study. J Clin Endocrinol Metab. 2010;95:3165-3172.
431. Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab. 1999;84:3681-3685.
432. Yaffe K, Lui LY, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc. 2002;50:707-712.
433. Yeap BB, Almeida OP, Hyde Z, et al. Higher serum free testosterone is associated with better cognitive function in older men, while total testosterone is not. The Health In Men Study. Clin Endocrinol (Oxf). 2008;68:404-412.
434. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
435. Tracz MJ, Sideras K, Boloña ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91:2011-2016.
436. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galván R. Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male. 2008;11:140-145.
437. Wang YJ, Zhan JK, Huang W, et al. Effects of low-dose testosterone undecanoate treatment on bone mineral density and bone turnover markers in elderly male osteoporosis with low serum testosterone. Int J Endocrinol. 2013;2013:570413.
438. Idan A, Griffiths KA, Harwood DT, et al. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Ann Intern Med. 2010;153:621-632.
439. Ruige JB, Ouwens DM, Kaufman JM. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab. 2013;98:4300-4310.
440. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
441. Basaria S, Davda MN, Travison TG, Ulloor J, Singh R, Bhasin S. Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2013;68:153-160.
442. Venken K, Boonen S, Van Herck E, et al. Bone and muscle protective potential of the prostate-sparing synthetic androgen 7α-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone. 2005;36:663-670.
443. Miner JN, Chang W, Chapman MS, et al. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007;148:363-373.
444. McCoy SC, Yarrow JF, Conover CF, et al. 17β-Hydroxyestra-4,9,11-trien-3-one (Trenbolone) preserves bone mineral density in skeletally mature orchiectomized rats without prostate enlargement. Bone. 2012;51:667-673.
445. Beck DT, Yarrow JF, Beggs LA, et al. Influence of aromatase inhibition on the bone-protective effects of testosterone. J Bone Miner Res. 2014;29:2405-2413.
446. Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14:335-345.
447. Matsumoto AM, Tenover L, McClung M, et al. The longterm effect of specific type II 5α-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002;167:2105-2108.
448. Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5α-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008;179:2333-2338.
449. Jacobsen SJ, Cheetham TC, Haque R, Shi JM, Loo RK. Association between 5-α reductase inhibition and risk of hip fracture. JAMA. 2008;300:1660-1664.
450. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89:503-510.
451. Bjørnerem A, Emaus N, Berntsen GK, et al. Circulating sex steroids, sex hormone-binding globulin, and longitudinal changes in forearm bone mineral density in postmenopausal women and men: the Tromsø study. Calcif Tissue Int. 2007;81:65-72.
452. Eriksson AL, Lorentzon M, Mellström D, et al. SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab. 2006;91:5029-5037.
453. Nyquist F, Gärdsell P, Sernbo I, Jeppsson JO, Johnell O. Assessment of sex hormones and bone mineral density in relation to occurrence of fracture in men: a prospective population-based study. Bone. 1998;22:147-151.
454. Mohr BA, Bhasin S, Kupelian V, Araujo AB, O'Donnell AB, McKinlay JB. Testosterone, sex hormone-binding globulin, and frailty in older men. J Am Geriatr Soc. 2007;55:548-555.
455. de Ronde W, van der Schouw YT, Muller M, et al. Associations of sex-hormone-binding globulin (SHBG) with non-SHBG-bound levels of testosterone and estradiol in independently living men. J Clin Endocrinol Metab. 2005;90:157-162.
456. Khosla S. Editorial: sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action? J Clin Endocrinol Metab. 2006;91:4764-4766.
457. Orwoll E, Lapidus JA, Wang Y, et al. Lack of value of serum sex steroid measures in the prediction of osteoporosis and fracture risk in community-dwelling, ambulatory older men. J Bone Miner Res. 2012;27:S66.
458. Orwoll E, Teglbjaerg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97:3161-3169.